Mode
Text Size
Log in / Sign up
N/A Completed N=255 Randomized Triple-blind Treatment

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

Source: ClinicalTrials.gov NCT05384041 ↗
Enrolled (actual)
255
Serious AEs
0.0%
Results posted
May 2023
Primary outcomePrimary: Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline. — 16.65; 14.36 units on a scale — p=0.056

Summary

This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline.
16.65; 14.36 0.056
SECONDARY
Change in the Beck Depression Inventory Second Edition (BDI-II) at Weeks One and Four Compared to Baseline.
14.1; 11.5; 19.9; 16.9 0.048 sig
SECONDARY
Change in the Patient Health Questionnaire-9 (PHQ-9) at Weeks One, Two, and Four Compared to Baseline.
5.27; 4.50; 7.46; 6.29; 8.88; 7.72 0.2595
SECONDARY
Change in the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) at Weeks One, Two, and Four Compared to Baseline.
5.53; 4.77; 6.72; 5.71; 7.99; 6.90 0.2065
SECONDARY
Beck Depression Inventory Second Edition (BDI-II) Responder Rate by Time Point (% of Subjects With a 50% or Better Improvement in Score From Baseline).
46; 38; 80; 91; 64; 55 0.231

Eligibility Criteria

Inclusion Criteria

  • Age 21-65 years and a resident of the United States of America
  • Meets DSM-5 diagnostic criteria for moderate to severe Major Depressive Disorder
  • Baseline BDI-II score between 20 and 63, inclusive (in moderate to severe range)
  • Able to receive packages to their home via United Parcel Service/Fedex/United States Postal Service or other delivery service
  • Willing and able to send and receive study related text messages on an internet capable mobile device throughout the duration of the study
  • Owns and uses a personal, verifiable email address
  • Able to commit to two (2) 20-minute treatment sessions per day for 4 weeks, one treatment upon waking for the day and one treatment before going to bed
  • Willing to abstain from use of recreational drugs, hypnotics, steroids, and/or marijuana products through study completion
  • Willingness to not initiate treatment for a mental health issue during the course of the study
  • Fluent in English
  • Sexually active females of childbearing potential willing to commit to practicing at least one or more of the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception, or abstinence
  • In the opinion of the investigator, able to comply with study requirements and complete the study

Exclusion Criteria

  • History of suicide attempt or active suicidal ideation with plan or intent in the past 30 days.
  • In the opinion of the investigator, considered high risk of suicide
  • Previous hospitalization or institutionalization for mental health condition within one year of study entry
  • Underwent electronic brain stimulation or neuromodulation within the past one year, including CES, transcranial magnetic stimulation, electroconvulsive therapy, and deep brain stimulation
  • Modification of prescription medications that affect the nervous system (e.g., psychotropic medications) within 30 days of study entry
  • Use of recreational drugs, hypnotics, steroids, and/or marijuana products in the past 30 days
  • History of alcohol use disorder or other substance use disorder in the past 12 months
  • Females currently pregnant or planning to conceive during study participation, or unwilling to comply with birth control requirements
  • Known history of heart disease
  • Known history of trigeminal neuralgia
  • Implanted with an electronic device such as a defibrillator, deep brain stimulator, or pacemaker
  • Unstable medical condition including any condition requiring hospitalization or change in treatment in the prior 30 days
  • Legally blind and/or deaf and without in-home care service to assist with study participation
  • Meets M.I.N.I. assessment criteria for, or has been diagnosed with, any of the following: Bipolar I disorder, bipolar II disorder, other specified bipolar and related disorder, panic disorder, agoraphobia, social anxiety disorder (social phobia), obsessive-compulsive disorder, posttraumatic stress disorder, alcohol use disorder in the past 12 months, substance use disorder (non-alcohol) in the past 12 months, any psychotic disorder (e.g., schizophrenia, schizoaffective disorder), major depressive disorder with psychotic features, anorexia nervosa, bulimia nervosa, binge-eating disorder, generalized anxiety disorder, any cognitive or developmental disorder (e.g., autism, Down's Syndrome), any personality disorder or psychiatric disorder that may interfere with study participation
  • Current participation in another investigational study or participated in an investigational study within the past 30 days
  • In the opinion of the investigator, may not be able to comply with study requirements
  • Any employee, family member, or personal associate of the Sponsor or their designees conducting the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05384041). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search